NCT03486067: Phase 1 - CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in relapsed Multiple Myeloma
Updated: May 26, 2022
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple myeloma.
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
Sponsor
Celgene
ClinicalTrials.gov Identifier: NCT03486067
First Posted : April 3, 2018
anti-BCMA/CD3 bispecific antibody CC-93269
BCMA x CD3 T Cell-engaging antibody CC-93269
BCMA/CD3 T-cell bi-specific antibody CC-93269
BCMA/CD3-directed bispecific T-cell engager antibody CC-93269
BCMAxCD3 BiTE antibody CC-93269
BCMAxCD3 TCB CC-93269
bi-specific antibody CC-93269
Drug: CC-93269
anti-BCMA/CD3 bispecific antibody CC-93269
- Alabama: University of Alabama at Birmingham
- California: University of California San Francisco
- Connecticut: Yale University New Haven
- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston
- Massachusetts: Massachusetts General Hospital Boston
- New York: Tisch Cancer Institute Mount Sinai Hospital New York
- Washington: Swedish Cancer Inst Seattle
Locations
United States, Alabama
United States, California
United States, Connecticut
United States, Georgia
United States, Massachusetts
United States, Michigan
United States, New York
United States, Washington
Europe
Germany
Italy
Spain
Sweden